Pulmonary sarcomatoid carcinoma presenting both ALK rearrangement and PD-L1 high positivity
Federica D’Antonio(Humanitas University), Armando Santoro(IRCCS Humanitas Research Hospital), Isabella Bolengo(Associated Press), Daoud Rahal(IRCCS Humanitas Research Hospital), Annarita Destro(Izumi City General Hospital), Fabio De Vincenzo(Humanitas University), Rita De Sanctis(Humanitas University)
Cited by 12
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670